BioTelemetry Says Court Restrains InfoBionic On Its Patent Issue

BioTelemetry, Inc. BEAT revealed that the District Court in the District of Massachusetts has reached Consent Judgment on July 14 permanently enjoining and restraining InfoBionic, Inc. on the patent enforcement issue.

According to the company, this included a curb on "making, using, offering to sell, or selling within the United States or importing into the United States" any of its "First-Generation" MoMe Kardia system and from "engaging in any other act of infringement" by its "First-Generation" system as defined under federal patent law.

BioTelemetry said it was happy with the initial outcome of the Court ruling and has pending patent infringement claims against InfoBionic's "Second-Generation" MoMe Kardia system and claims for misappropriation of its trade secrets.

The company asserted that such trade secrets were misappropriated partly by one or more former BioTelemetry executives and employees who joined InfoBionic and were involved in the development of its MoMe Kardia system.

BEAT ended Tuesday's trading at $17.67.